<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001256683
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SACVALY
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SACUBITRIL,VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        49,51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        344.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sacvaly is a medicine containing an angiotensin receptor neprilysin inhibitor. It delivers two active substances, sacubitril and valsartan.</p><p>Sacvaly is used to treat a type of long-term heart failure in adults.</p><p>This type of heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and the rest of the body. The most common symptoms of heart failure are breathlessness, fatigue, tiredness and ankle swelling.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Sacvaly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to sacubitril, valsartan or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking another type of medicine called an angiotensin converting enzyme (ACE) inhibitor (for example enalapril, lisinopril or ramipril). ACE inhibitors are used to treat high blood pressure</p><p>or heart failure. If you have been taking an ACE inhibitor, wait for 36 hours after taking the last dose before you start to take Sacvaly (see &ldquo;Other medicines and Sacvaly&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or a member of your family have ever had a reaction called angioedema (swelling of the face, lips, tongue and/or throat, difficulties in breathing) when taking an ACE inhibitor or an angiotensin receptor blocker (ARB) (such as valsartan, telmisartan or irbesartan).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are being treated with a blood pressure lowering medicine containing aliskiren (see &ldquo;Other medicines and Sacvaly&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant (it is also better to avoid this medicine in early pregnancy, see &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p>If any of the above applies to you, do not take Sacvaly and talk to your doctor. Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before or when taking Sacvaly:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated with an angiotensin receptor blocker (ARB) or aliskiren (see &ldquo;Do not take Sacvaly&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had angioedema (see &ldquo;Do not take Sacvaly&rdquo; and section 4 &ldquo;Possible sideeffects&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood pressure or are taking any other medicines that reduce your blood pressure (for example, a diuretic) or are suffering from vomiting or diarrhoea, especially if you are aged 65 years or more, or if you have kidney disease and low blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suffering from dehydration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your kidney artery has narrowed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience hallucinations, paranoia or changes in sleeping pattern.</p><p>Your doctor may check the amount of potassium in your blood at regular intervals during Sacvaly treatment.</p><p>If any of the above applies to you, tell your doctor, pharmacist or nurse before you take Sacvaly Children and adolescents</p><p>Do not give this medicine to children (aged below 18 years) because it has not been studied in this age group.</p><p>&nbsp;</p><p>Other medicines and Sacvaly</p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. It may be necessary to change the dose, to take other precautions, or even to stop taking one of the medicines. This is particularly important for the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors. Do not take Sacvaly with ACE inhibitors. If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Sacvaly (see &ldquo;Do not Sacvaly&rdquo;). If you stop taking FAVVAL-SCT, wait 36 hours after taking your last dose of Sacvaly before starting an ACE inhibitor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines used to treat heart failure or lower blood pressure, such as angiotensin receptor blockers or aliskiren (see &ldquo;Do not take Sacvaly&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines known as statins that are used to lower high cholesterol levels (for example atorvastatin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil, a medicine used to treat erectile dysfunction or lung hypertension.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that increase the amount of potassium in the blood. These include potassium supplements, salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painkillers of the type called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 (Cox-2) inhibitors. If you are taking one of these, your doctor may want to check your kidney function when starting or adjusting treatment (see &ldquo;Warnings and precautions&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium, a medicine used to treat some types of psychiatric illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; furosemide, a medicine belonging to the type known as diuretics, which are used to increase the amount of urine you produce.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nitroglycerine, a medicine used to treat angina pectoris.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some types of antibiotics (rifamycin group), ciclosporin (used to prevent rejection of transplanted organs) or antivirals such as ritonavir (used to treat HIV/AIDS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, a medicine used to treat diabetes.</p><p>If any of the above applies to you, tell your doctor or pharmacist before you take Sacvaly Pregnancy and breastfeeding</p><p><u>Pregnancy</u></p><p>You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Sacvaly.</p><p>This medicine is not recommended in early pregnancy, and must not be taken when more than</p><p>3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p><u>Breast-feeding</u></p><p>Sacvaly is not recommended for mothers who are breast-feeding. Tell your doctor if you are breast- feeding or about to start breast-feeding.</p><p>Driving and using machines</p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Sacvaly affects you. If you feel dizzy or very tired while taking this medicine, do not drive a vehicle, cycle or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>You will usually start by taking 24 mg/26 mg or 49 mg/51 mg twice a day (one tablet in the morning and one tablet in the evening). Your doctor will decide your exact starting dose based on which medicines you have been taking previously. Your doctor will then adjust the dose depending on how you respond to the treatment until the best dose for you is found.</p><p>The usual recommended target dose is 97 mg/103 mg twice a day (one tablet in the morning and one tablet in the evening).</p><p>Patients taking Sacvaly can develop low blood pressure (dizziness, light-headedness), a high level of potassium in the blood (which would be detected when your doctor performed a blood test) or decreased kidney function. If this happens, your doctor may reduce the dose of any other medicine you are taking, temporarily reduce your Sacvaly dose, or stop your Sacvaly treatment completely.</p><p>Swallow the tablets with a glass of water. You can take Sacvaly with or without food. Splitting or crushing of the tablets is not recommended.</p><p>If you take more Sacvaly than you should</p><p>If you have accidentally taken too many Sacvaly tablets, or if someone else has taken your tablets,</p><p>contact your doctor immediately. If you experience severe dizziness and/or fainting, tell your doctor as quickly as possible and lie down.</p><p>If you forget to take Sacvaly</p><p>It is advisable to take your medicine at the same time each day. However, if you forget to take a dose, you should simply take the next one at the scheduled time. Do not take a double dose to make up for a forgotten tablet.</p><p>If you stop taking Sacvaly</p><p>Stopping your treatment with Sacvaly may cause your condition to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some side effects may be serious.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop taking Sacubitril and Valsartan and seek immediate medical attention if you notice anyswelling of the face, lips, tongue and/or throat, which may cause difficulties in breathing orswallowing. These may be signs of angioedema (an uncommon side effect which may affect up to 1in 100 people).</p><p>Other possible side effects:</p><p>If any of the side effects listed below becomes severe, tell your doctor or pharmacist.</p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (dizziness, light-headedness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of potassium in the blood (shown in a blood test)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased renal function (renal impairment)</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of red blood cells (shown in a blood test)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (acute) renal failure (severe kidney disorder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of potassium in the blood (shown in a blood test)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (dizziness, light-headedness) when switching from sitting or lying to standing position</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastritis (stomach pain, nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of sugar in the blood (shown in a blood test)</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction with rash and itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness when switching from sitting to standing position</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sleeping pattern</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paranoia</p><p>&nbsp;</p><p><strong>Reporting of side effects&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If you have any suspension left in the bottle more than 90 days after it was first opened, do not use it.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Sacubitril and Valsartan</p><p>Each Film Coated tablet contains 24mg of Sacubitril and 26mg of Valsartan.</p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides and Titanium Dioxide.</p><p>Sacvaly 51/49:</p><p>The active substance is Sacubitril and Valsartan</p><p>Each Film Coated tablet contains 49mg of Sacubitril and 51 mg of Valsartan.</p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides, Titanium Dioxide, FD&amp;C blue #2/Indigo Carmine AL 3% and 5% and FD&amp;C blue #2/Indigo Carmine Aluminum lake.</p><p>Sacvaly 103/97:</p><p>The active substance is Sacubitril and Valsartan</p><p>Each Film Coated tablet contains 97mg of Sacubitril and 103mg of Valsartan.</p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides, Iron oxide Red and Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Sacvaly looks like?

Sacvaly 26/24
White colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S24’ on the other side.

Sacvaly 51/49
Blue colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S25’ on the other side.
Sacvaly 103/97
Brown colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S26’ on the other side.

How supplied:
Tablets are supplied in Blister pack contain 60 Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company </strong></p><p>Aljameah Street, Malaz quarter,</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel: +966 11 226 8850</p><p>Manufacturer:</p><p>Heter Labs Limited Unit III, India</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 2022 December, Version 1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يعمل دواء ساكفالي كمثبط لمستقبلات الأنجيوتنسين نيبريليزين &quot; angiotensin receptor neprilysin inhibitor&quot;. حيث يحتوي على اثنين من المواد الفعالة ، ساكوبيتريل وفالسارتان.</p><p dir="RTL">يستخدم ساكفالي لعلاج نوع من قصور القلب طويل الأمد لدى البالغين.</p><p dir="RTL">يحدث هذا النوع من قصور القلب عندما يكون القلب ضعيفًا ولا يستطيع ضخ كمية كافية من الدم إلى الرئتين وبقية الجسم. أكثر أعراض قصور القلب شيوعًا هي ضيق التنفس والتعب والإرهاق وتورم الكاحل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>لا تستخدم ساكفالي أقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ساكوبيتريل أو فالسارتان أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول نوعًا آخر من الأدوية يسمى مثبط الإنزيم المحول للأنجيوتنسين (على سبيل المثال إنالابريل أو ليسينوبريل أو راميبريل). تستخدم مثبطات الإنزيم المحول للأنجيوتنسين لعلاج ارتفاع ضغط الدم أو قصور القلب. إذا كنت تتناول أحد مثبطات الإنزيم المحول للأنجيوتنسين ، فانتظر لمدة 36 ساعة بعد تناول آخر جرعة قبل أن تبدأ في تناول ساكفالي (انظر &quot; الأدوية الأخرى وتناول ساكفالي أقراص&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت أنت أو أحد أفراد عائلتك من رد فعل تحسسي يسمى الوذمة الوعائية (تورم الوجه ، الشفتين ، اللسان و / أو الحلق ، صعوبات في التنفس) عند تناول مثبطات الإنزيم المحول للأنجيوتنسين أو حاصرات مستقبلات الأنجيوتنسين (ARB) (مثل فالسارتان أو تيلميسارتان أو إربيسارتان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السكري أو ضعف في وظائف الكلى وتعالج بدواء لخفض ضغط الدم يحتوي على أليسكيرين (انظر &quot; الأدوية الأخرى وتناول ساكفالي أقراص &quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كبدي حاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً لأكثر من 3 أشهر (من الأفضل أيضًا تجنب هذا الدواء في بداية الحمل ، أنظري &quot;الحمل والرضاعة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انطبق عليك أي مما سبق ، فلا تتناول ساكفالي وتحدث مع طبيبك.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل أو أثناء تناول ساكفالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعالج بمانع مستقبلات الأنجيوتنسين (ARB) أو أليسكيرين (انظر &quot; لا تستخدم ساكفالي أقراص &quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك وذمة وعائية في أي وقت مضى (انظر &quot; لا تستخدم ساكفالي أقراص &quot; والقسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض في ضغط الدم أو كنت تتناول أي أدوية أخرى تقلل من ضغط الدم (على سبيل المثال ، مدر للبول) أو كنت تعاني من القيء أو الإسهال ، خاصة إذا كان عمرك 65 عامًا أو أكثر ، أو إذا كنت تعاني من مرض في الكلى و ضغط دم منخفض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض شديد في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تضيق شريان الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كبدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الهلوسة أو جنون العظمة أو تغيرات في نمط النوم.</p><p dir="RTL">قد يقوم طبيبك بفحص كمية البوتاسيوم في دمك على فترات منتظمة خلال فترة علاج باستخدام ساكفالي.</p><p dir="RTL">إذا انطبق عليك أي مما سبق ، أخبر طبيبك أو الصيدلي أو الممرضة قبل تناول ساكفالي.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء للأطفال (الذين تقل أعمارهم عن 18 عامًا) لأنه لم تتم دراسته في هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى وتناول ساكفالي أقراص</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. قد يكون من الضروري تغيير الجرعة أو اتخاذ احتياطات أخرى أو حتى التوقف عن تناول أحد الأدوية. هذا مهم بشكل خاص للأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات ACE. لا تتناول ساكفالي مع مثبطات الإنزيم المحول للأنجيوتنسين. إذا كنت تتناول مثبطات الإنزيم المحول للأنجيوتنسين ، فانتظر 36 ساعة بعد تناول آخر جرعة من مثبط الإنزيم المحول للأنجيوتنسين قبل البدء في تناول ساكفالي (انظر &quot;لا تستخدم ساكفالي أقراص&quot;). إذا توقفت عن تناول ساكفالي ، انتظر 36 ساعة بعد تناول آخر جرعة من ساكفالي قبل البدء في تناول مثبطات الإنزيم المحول للأنجيوتنسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستخدمة لعلاج قصور القلب أو انخفاض ضغط الدم ، مثل حاصرات مستقبلات الأنجيوتنسين أو أليسكيرين (انظر &quot;لا تستخدم ساكفالي أقراص&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المعروفة باسم الستاتينات التي تستخدم لخفض مستويات الكوليسترول المرتفعة (على سبيل المثال أتورفاستاتين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل ، دواء يستخدم لعلاج ضعف الانتصاب أو ارتفاع ضغط الدم في الرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من كمية البوتاسيوم في الدم. وتشمل مكملات البوتاسيوم وبدائل الملح التي تحتوي على البوتاسيوم والأدوية التي تحافظ على البوتاسيوم والهيبارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسكنات من النوع الذي يسمى مضادات الالتهاب غير الستيرويدية (NSAIDs) أو مثبطات انزيمات الأكسدة الحلقية 2 الانتقائية (Cox-2). إذا كنت تتناول أحد هذه الأدوية ، فقد يرغب طبيبك في فحص وظائف الكلى عند بدء العلاج أو تعديله (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم وهو دواء يستخدم لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوروسيميد ، دواء ينتمي إلى النوع المعروف باسم مدرات البول ، والتي تستخدم لزيادة كمية البول التي تفرزها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النتروجليسرين وهو دواء يستخدم في علاج الذبحة الصدرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع المضادات الحيوية (مجموعة ريفاميسين) ، سيكلوسبورين (تستخدم لمنع رفض الأعضاء المزروعة) أو مضادات الفيروسات مثل ريتونافير (تستخدم لعلاج فيروس نقص المناعة البشرية / الإيدز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميتفورمين ، دواء يستخدم لعلاج مرض السكري.</p><p dir="RTL">إذا انطبق عليك أي مما سبق ، أخبر طبيبك أو الصيدلي قبل تناول ساكفالي</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبر طبيبك إذا كنت تعتقدين أنك (أو قد تصبحين) حاملاً. سينصحك طبيبك عادة بالتوقف عن تناول هذا الدواء قبل الحمل أو بمجرد أن تعرفين أنك حامل ، وسوف ينصحك بتناول دواء آخر بدلاً من ساكفالي.</p><p dir="RTL">لا ينصح بهذا الدواء في بداية الحمل ، ويجب عدم تناوله خلال أكثر من 3 أشهر من الحمل ، حيث أنه قد يسبب ضررًا خطيرًا لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">لا ينصح باستخدام ساكفالي للأمهات المرضعات. أخبر طبيبك إذا كنت ترضعين أو على وشك البدء في الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قبل قيادة السيارة أو استخدام الأدوات أو تشغيل الآلات أو القيام بأنشطة أخرى تتطلب التركيز ، تأكد من معرفة مدى تأثير ساكفالي عليك. إذا شعرت بدوار أو إرهاق شديد أثناء تناول هذا الدواء ، فلا يجوز قيادة السيارة أو ركوب الدراجة أو استخدام أي أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">ستبدأ عادة بتناول 24 ملجرام / 26 ملجرام أو 49 ملجرام / 51 ملجرام مرتين في اليوم (قرص واحد في الصباح وقرص واحد في المساء). سيقرر طبيبك جرعة البدء الدقيقة بناءً على الأدوية التي كنت تتناولها سابقًا. سيقوم طبيبك بعد ذلك بتعديل الجرعة اعتمادًا على كيفية استجابتك للعلاج حتى يتم الوصول لأفضل جرعة لك.</p><p dir="RTL">الجرعة المعتادة الموصى بها هي 97 ملجرام / 103 ملجرام مرتين في اليوم (قرص في الصباح وقرص في المساء).</p><p dir="RTL">يمكن للمرضى الذين يتناولون ساكفالي أن يصابوا بانخفاض في ضغط الدم (دوار ، خفة الرأس) ، ارتفاع مستوى البوتاسيوم في الدم (والذي يمكن اكتشافه عندما يقوم طبيبك بإجراء فحص الدم) أو انخفاض في وظائف الكلى. إذا حدث هذا ، فقد يقوم طبيبك بتقليل جرعة أي دواء آخر تتناوله ، أو يقلل مؤقتًا من جرعة ساكفالي ، أو يوقف علاج ساكفالي تمامًا.</p><p dir="RTL">ابتلاع الأقراص مع كوب من الماء. يمكنك تناول ساكفالي مع الطعام أو بدونه. لا ينصح بشق أو سحق الأقراص.</p><p dir="RTL"><strong>تناول جرعة زائدة من ساكفالي أقراص</strong></p><p dir="RTL">إذا تناولت عن طريق الخطأ عددًا كبيرًا جدًا من أقراص ساكفالي ، أو إذا تناول شخص آخر أقراصك ،</p><p dir="RTL">اتصل بطبيبك على الفور. إذا شعرت بدوخة شديدة و / أو إغماء ، أخبر طبيبك بأسرع ما يمكن واستلق.</p><p dir="RTL"><strong>إذا نسيت أن تتناول ساكفالي</strong></p><p dir="RTL">يُنصح بتناول دوائك في نفس الوقت كل يوم. ومع ذلك ، إذا نسيت تناول جرعة ، فعليك ببساطة تناول الجرعة التالية في الوقت المحدد. لا تتناول جرعة مضاعفة لتعويض قرص منسي.</p><p dir="RTL"><strong>التوقف عن تناول ساكفالي</strong></p><p dir="RTL">قد يؤدي إيقاف العلاج باستخدام ساكفالي إلى تفاقم حالتك. لا تتوقف عن تناول دوائك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تكون بعض الآثار الجانبية خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف عن تناول ساكوبيتريل وفالسارتان واطلب العناية الطبية على الفور إذا لاحظت أي تورم في الوجه والشفتين واللسان و / أو الحلق ، مما قد يسبب صعوبات في التنفس أو البلع. قد تكون هذه علامات على وذمة وعائية (عرض جانبي غير شائع قد يؤثر على ما يصل إلى 1 من كل 100 شخص).</p><p dir="RTL">الآثار الجانبية المحتملة الأخرى:</p><p dir="RTL">إذا أصبحت أي من الآثار الجانبية المذكورة أدناه شديدة ، أخبر طبيبك أو الصيدلي.</p><p dir="RTL">شائع جدًا (قد يصيب أكثر من 1 من كل 10 أشخاص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (دوار ، خفة الرأس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم في الدم (يظهر في فحص الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض وظائف الكلى (القصور الكلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة (قد تظهر لدى حتى 1 من كل 10 أشخاص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم الحمراء (كما هو موضح في فحص الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي (الحاد) (اضطراب كلوي حاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم (يظهر في فحص الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (دوار ، خفة الرأس) عند التبديل من الجلوس أو الاستلقاء إلى وضعية الوقوف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة (آلام في المعدة ، غثيان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوران</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم (كما هو موضح في فحص الدم).</p><p dir="RTL">غير شائعة (قد تظهر لدى حتى 1 من كل 100 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي مع طفح جلدي وحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار عند التبديل من وضعية الجلوس إلى الوقوف</p><p dir="RTL">نادرة (قد تظهر لدى حتى 1 من كل 1000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلوسة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نمط النوم</p><p dir="RTL">نادرة جدًا (قد تظهر لدى حتى 1 من بين 10000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جنون العظمة</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا المنتج الطبي أي شروط تخزين خاصة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ساكفالي أقراص على:</strong></p><p dir="RTL">المواد الفعالة هي ساكوبيتريل وفالسارتان<strong> </strong></p><p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 24 ملجرام / 26 ملجرام:</strong></p><p dir="RTL">يحتوي كل قرص مغلف على 24 ملجرام من ساكوبيتريل و 26 ملجرام من فالسارتان.</p><p dir="RTL">الصواغات الأخرى هي: السليلوز دقيق التبلور ، هيدروكسي بروبيل منخفض الاستبدال ، بوفيدون ، كحول الأيزوبروبيل ، كروسبوفيدون ، ثاني أكسيد السيليكون ، ستيرات الماغنيسيوم وكلوريد الميثيلين.</p><p dir="RTL">الصواغات الأخرى لطبقة الكسوة الخارجية هي: HPMC 2910/هيبروميلوز ، أحادي الجليسريد ثنائي الأسيتيل وثاني أكسيد التيتانيوم.</p><p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 49 ملجرام / 51 ملجرام: </strong></p><p dir="RTL">يحتوي كل قرص مغلف على 49 ملجرام من ساكوبيتريل و 51 ملجرام من فالسارتان.</p><p dir="RTL">الصواغات الأخرى هي: السليلوز دقيق التبلور ، هيدروكسي بروبيل منخفض الاستبدال ، بوفيدون ، كحول الأيزوبروبيل ، كروسبوفيدون ، ثاني أكسيد السيليكون ، ستيرات الماغنيسيوم وكلوريد الميثيلين.</p><p dir="RTL">الصواغات الأخرى لطبقة الكسوة الخارجية هي: - HPMC 2910 / هيبميلوز ، أحادي الجليسريد ثنائي الأسيتيل ، ثاني أكسيد التيتانيوم ، صبغة زرقاء FD&amp;C blue # 2 / Indigo Carmine AL 3٪ and 5٪ and صبغة زرقاء FD&amp;C blue # 2 / Indigo Carmine Aluminium Lake.</p><p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 97 ملجرام / 103 ملجرام: </strong></p><p dir="RTL">يحتوي كل قرص مغلف على 97 ملجرام من ساكوبيتريل و 103 ملجرام من فالسارتان.</p><p dir="RTL">الصواغات الأخرى هي: السليلوز دقيق التبلور ، هيدروكسي بروبيل منخفض الاستبدال ، بوفيدون ، كحول الأيزوبروبيل ، كروسبوفيدون ، ثاني أكسيد السيليكون ، ستيرات الماغنيسيوم وكلوريد الميثيلين.</p><p dir="RTL">الصواغات الأخرى لطبقة الكسوة الخارجية هي: - HPMC 2910 / هيبروميلوز ، أحادي الجليسريد ثنائي الأسيتيل ، أكسيد الحديد الأحمر وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 24 ملجرام / 26 ملجرام:</strong></p><p dir="RTL">أقراص بيضاوية الشكل بيضاء اللون ، مغلفة بالفيلم منقوش عليها حرف &quot;H&quot; على جانب واحد و &quot;S24&quot; على الجانب الآخر.</p><p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 49 ملجرام / 51 ملجرام: </strong></p><p dir="RTL">أقراص بيضاوية الشكل مطلية باللون الأزرق ، منقوش عليها حرف &quot;H&quot; على جانب واحد و &quot;S25&quot; على الجانب الآخر.</p><p dir="RTL"><strong>ساكفالي </strong><strong>أقراص</strong><strong> 97 ملجرام / 103 ملجرام: </strong></p><p dir="RTL">أقراص بيضاوية الشكل مطلية باللون البني ، منقوش عليها حرف &quot;H&quot; على جانب واحد و &quot;S26&quot; على الجانب الآخر.</p><p dir="RTL"><strong>كيفية توفير ساكفالي أقراص؟</strong></p><p dir="RTL">يتم توفير أقراص ساكفالي في عبوات تحتوي على شرائط بها 60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>شركة اماروكس السعودية الصناعية</strong></p><p>شارع الجامعة &ndash; الملز &ndash; الرياض 12629</p><p>المملكة العربية السعودية.</p><p>تليفون: 966112268850+</p><p><strong>المصنع:</strong></p><p dir="RTL">شركة هيتيرو لاب المحدودة - الوحدة الثالثة، الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في ديسمبر 2022 ، نسخة 1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sacvaly (Sacubitril and Valsartan Tablets 24mg/26mg, 49mg/51mg and 97mg/103mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sacvaly (Sacubitril and Valsartan Tablets 24mg/26mg)
Each film coated tablet contains 24mg of Sacubitril and 26mg ofValsartan Sacvaly (Sacubitril and Valsartan Tablets 49mg/51mg)
Each film coated tablet contains 49mg of Sacubitril and 51 mg of Valsartan Sacvaly (Sacubitril and Valsartan Tablets 97mg/103mg)
Each film coated tablet contains 97mg of Sacubitril and 103mg of Valsartan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sacvaly (Sacubitril and Valsartan Tablets 26mg/24mg)
White colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S24’ on the other side.
Sacvaly (Sacubitril and Valsartan Tablets 51mg/49mg)
Blue colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S25’ on the other side.
Sacvaly (Sacubitril and Valsartan Tablets 103mg/97mg)
Brown colored, Oval shaped, film coated tablets debossed with ‘H’ on one side and ‘S26’ on the other side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp; </strong><strong>Therapeutic indications</strong></p><p>Sacvaly is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The recommended starting dose of Sacvaly is one tablet of 49 mg/51 mg twice daily, except in the situations described below. The dose should be doubled at 2-4 weeks to the target dose of one tablet of 97 mg/103 mg twice daily, as tolerated by the patient (see section 5.1).</p><p>If patients experience tolerability issues (systolic blood pressure [SBP] &le;95 mmHg, symptomatic hypotension, hyperkalaemia, renal dysfunction), adjustment of concomitant medicinal products, temporary down&ndash;titration or discontinuation of Sacvaly is recommended (see section 4.4).</p><p>In PARADIGM-HF study, Sacvaly was administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin II receptor blocker (ARB) (see section 5.1). There is limited experience in patients not currently taking an ACE inhibitor or an ARB or taking low doses of these medicinal products, therefore a starting dose of 24 mg/26 mg twice daily and slow dose titration (doubling every 3-4 weeks) are recommended in these patients (see &ldquo;Titration&rdquo; in section 5.1).</p><p>Treatment should not be initiated in patients with serum potassium level &gt;5.4 mmol/l or with SBP &lt;100 mmHg (see section 4.4). A starting dose of 24 mg/26 mg twice daily should be considered for patients with SBP &ge;100 to 110 mmHg.</p><p>Sacvaly should not be co-administered with an ACE inhibitor or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, it must not be started for at least 36 hours after discontinuing ACE inhibitor therapy (see sections 4.3, 4.4 and 4.5).</p><p>The valsartan contained within Sacvaly is more bioavailable than the valsartan in other marketed tablet formulations (see section 5.2).</p><p>If a dose is missed, the patient should take the next dose at the scheduled time. Splitting or crushing of the tablets is not recommended.</p><p>Special populations Elderly population</p><p>The dose should be in line with the renal function of the elderly patient. Renal impairment</p><p>No dose adjustment is required in patients with mild (Estimated Glomerular Filtration Rate [eGFR] 60-90 ml/min/1.73 m2) renal impairment. A starting dose of 24 mg/26 mg twice daily should be considered in patients with moderate renal impairment (eGFR 30-60 ml/min/1.73 m2).</p><p>As there is very limited clinical experience in patients with severe renal impairment (eGFR &lt;30 ml/min/1.73 m2) (see section 5.1) Sacvaly should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended. There is no experience in patients with end-stage renal disease and use of Sacvaly is not recommended.</p><p>Hepatic impairment</p><p>No dose adjustment is required when administering Sacvaly to patients with mild hepatic impairment (Child-Pugh A classification). There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh B classification) or with AST/ALT values more than twice the upper limit of the normal range. Sacvaly should be used with caution in these patients and the recommended starting dose is 24 mg/26 mg twice daily (see sections 4.4 and 5.2). Sacvaly is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child-Pugh C classification) (see section 4.3).</p><p>Paediatric population</p><p>The safety and efficacy of Sacvaly in children and adolescents aged below 18 years have not been established. No data are available.</p><p>Method of administration Oral use.</p><p>Sacvaly may be administered with or without food (see section 5.2). The tablets must be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
•	Concomitant use with ACE inhibitors (see sections 4.4 and 4.5). Sacvaly must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
•	Known history of angioedema related to previous ACE inhibitor or ARB therapy (see section 4.4).
•	Hereditary or idiopathic angioedema (see section 4.4).
•	Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.4 and 4.5).
•	Severe hepatic impairment, biliary cirrhosis and cholestasis (see section 4.2).
•	Second and third trimesters of pregnancy (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&bull;&nbsp;&nbsp; The combination of sacubitril/valsartan with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of ACE inhibitor therapy. If treatment with sacubitril/valsartan is stopped, ACE inhibitor therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.2, 4.3 and 4.5).</p><p>&bull;&nbsp;&nbsp;&nbsp; The combination of sacubitril/valsartan with direct renin inhibitors such as aliskiren is not recommended (see section 4.5). The combination of sacubitril/valsartan with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt;60 ml/min/1.73 m2) (see sections 4.3 and 4.5).</p><p>&bull;&nbsp;&nbsp;&nbsp; Sacvaly contains valsartan, and therefore should not be co-administered with another ARB containing medicinal product (see sections 4.2 and 4.5).</p><p><u>Hypotension</u></p><p>Treatment should not be initiated unless SBP is &ge;100 mmHg. Patients with SBP &lt;100 mmHg were not studied (see section 5.1). Cases of symptomatic hypotension have been reported in patients treated with sacubitril/valsartan during clinical studies (see section 4.8), especially in patients &ge;65 years old, patients with renal disease and patients with low SBP (&lt;112 mmHg). When initiating therapy or during dose titration with sacubitril/valsartan, blood pressure should be monitored routinely. If hypotension occurs, temporary down-titration or discontinuation of sacubitril/valsartan is recommended (see section 4.2). Dose adjustment of diuretics, concomitant antihypertensives and treatment of other causes of hypotension (e.g. hypovolaemia) should be considered. Symptomatic hypotension is more likely to occur if the patient has been volume- depleted, e.g. by diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Sodium and/or volume depletion should be corrected before starting treatment with sacubitril/valsartan, however, such corrective action must be carefully weighed against the risk of volumeoverload.</p><p><u>Impaired renal function</u></p><p>Evaluation of patients with heart failure should always include assessment of renal function. Patients with mild and moderate renal impairment are more at risk of developing hypotension (see section 4.2). There is very limited clinical experience in patients with severe renal impairment (estimated GFR &lt;30 ml/min/1.73m2) and these patients may be at greatest risk of hypotension (see section 4.2). There is no experience in patients with end-stage renal disease and use of sacubitril/valsartan is not recommended.</p><p><u>Worsening renal function</u></p><p>Use of sacubitril/valsartan may be associated with decreased renal function. The risk may be further increased by dehydration or concomitant use of non-steroidal anti-inflammatory agents (NSAIDs) (see section 4.5). Down-titration should be considered in patients who develop a clinically significant decrease in renal function.</p><p><u>Hyperkalaemia</u></p><p>Treatment should not be initiated if the serum potassium level is &gt;5.4 mmol/l. Use of sacubitril/valsartan may be associated with an increased risk of hyperkalaemia, although hypokalaemia may also occur (see section 4.8). Monitoring of serum potassium is recommended, especially in patients who have risk factors such as renal impairment, diabetes mellitus or hypoaldosteronism or who are on a high potassium diet or on mineralocorticoid antagonists (see section 4.2). If patients experience clinically significant hyperkalaemia adjustment of concomitant medicinal products, or temporary down&ndash;titration or discontinuation is recommended. If serum potassium level is &gt;5.4 mmol/l discontinuation should be considered.</p><p><u>Angioedema</u></p><p>Angioedema has been reported in patients treated with sacubitril/valsartan. If angioedema occurs, sacubitril/valsartan should be immediately discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. It must not be re-administered. In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx likely to cause airway obstruction, appropriate therapy, e.g. adrenaline</p><p>solution 1 mg/1 ml (0.3-0.5 ml), and/or measures necessary to ensure a patent airway, should be promptly administered.</p><p>Patients with a prior history of angioedema were not studied. As they may be at higher risk for angioedema, caution is recommended if sacubitril/valsartan is used in these patients. sacubitril/valsartan is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy or with hereditary or idiopathic angioedema (see section 4.3).</p><p>Black patients have an increased susceptibility to develop angioedema (see section 4.8). <u>Patients with renal artery stenosis</u></p><p>Sacubitril/valsartan may increase blood urea and serum creatinine levels in patients with bilateral or unilateral renal artery stenosis. Caution is required in patients with renal artery stenosis and monitoring of renal function is recommended.</p><p><u>Patients with NYHA functional classification IV</u></p><p>Caution should be exercised when initiating sacubitril/valsartan in patients with NYHA functional classification IV due to limited clinical experience in this population.</p><p><u>B-type natriuretic peptide (BNP)</u></p><p>BNP is not a suitable biomarker of heart failure in patients treated with sacubitril/valsartan because it is a neprilysin substrate (see section 5.1).</p><p><u>Patients with hepatic impairment</u></p><p>There is limited clinical experience in patients with moderate hepatic impairment (Child-Pugh B classification) or with AST/ALT values more than twice the upper limit of the normal range. In these patients, exposure may be increased and safety is not established. Caution is therefore recommended when using it in these patients (see section 4.2 and 5.2). Sacubitril/valsartan is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (Child- Pugh C classification) (see section 4.3).</p><p><u>Psychiatric disorders</u></p><p>Psychiatric events such as hallucinations, paranoia and sleep disorders, in context of psychotic events, have been associated with sacubitril/valsartan use. If a patient experiences such events, discontinuation of sacubitril/valsartan treatment should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions resulting in a contraindication</u> ACE inhibitors</p><p>The concomitant use of sacubitril/valsartan with ACE inhibitors is contraindicated, as the concomitant inhibition of neprilysin (NEP) and ACE may increase the risk of angioedema. Sacubitril/valsartan must not be started until 36 hours after taking the last dose of ACE inhibitor therapy. ACE inhibitor therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.2 and 4.3).</p><p>Aliskiren</p><p>The concomitant use of sacubitril/valsartan with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt;60 ml/min/1.73 m2) (see section 4.3). The combination of sacubitril/valsartan with direct renin inhibitors such as aliskiren is not recommended (see section 4.4). Combination of sacubitril/valsartan with aliskiren is potentially associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) (see sections 4.3 and 4.4).</p><p><u>Interactions resulting in concomitant use not being recommended</u></p><p>Sacubitril/valsartan contains valsartan, and therefore should not be co-administered with another ARB containing medicinal product (see section 4.4).</p><p><u>Interactions requiring precautions</u></p><p>OATP1B1 and OATP1B3 substrates, e.g. statins</p><p>In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1B3 transporters. Sacvaly may therefore increase the systemic exposure of OATP1B1 and OATP1B3 substrates such as statins. Co-administration of sacubitril/valsartan increased the Cmax of atorvastatin and its metabolites by up to 2-fold and AUC by up to 1.3-fold. Caution should be exercised when co-administering sacubitril/valsartan with statins. No clinically relevant interaction was observed when simvastatin and Sacvaly were co-administered.</p><p>PDE5 inhibitors including sildenafil</p><p>Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil or another PDE5 inhibitor is initiated in patients treated with sacubitril/valsartan.</p><p>Potassium</p><p>Concomitant use of potassium-sparing diuretics (triamterene, amiloride), mineralocorticoid antagonists (e.g. spironolactone, eplerenone), potassium supplements, salt substitutes containing potassium or other agents (such as heparin) may lead to increases in serum potassium, and to increases in serum creatinine. Monitoring of serum potassium is recommended if sacubitril/valsartan is co-administered with these agents (see section 4.4).</p><p>Non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 (COX- 2) inhibitors</p><p>In elderly patients, volume-depleted patients (including those on diuretic therapy), or patients with compromised renal function, concomitant use of sacubitril/valsartan and NSAIDs may lead to an increased risk of worsening of renal function. Therefore, monitoring of renal function is recommended when initiating or modifying treatment in patients on sacubitril/valsartan who are taking NSAIDs concomitantly (see section 4.4).</p><p>Lithium</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors or angiotensin II receptor antagonists including sacubitril/valsartan. Therefore, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased further.</p><p>Furosemide</p><p>Co-administration of sacubitril/valsartan and furosemide had no effect on the pharmacokinetics of sacubitril/valsartan but reduced Cmax and AUC of furosemide by 50% and 28%, respectively. While there was no relevant change in urine volume, the urinary excretion of sodium was reduced within 4 hours and 24 hours after co-administration. The average daily dose of</p><p>furosemide was unchanged from baseline until the end of the PARADIGM-HF study in patients treated with sacubitril/valsartan.</p><p>Nitrates, e.g. nitroglycerine</p><p>There was no drug-drug interaction between sacubitril/valsartan and intravenously administered nitroglycerin with regard to blood pressure reduction. Co-administration of nitroglycerin and sacubitril/valsartan was associated with a treatment difference of 5 bpm in heart rate compared to the administration of nitroglycerine alone. A similar effect on the heart rate may occur when sacubitril/valsartan is co-administered with sublingual, oral or transdermal nitrates. In general no dose adjustment is required.</p><p>OATP and MRP2 transporters</p><p>The active metabolite of sacubitril (LBQ657) and valsartan are OATP1B1, OATP1B3, OAT1 and OAT3 substrates; valsartan is also a MRP2 substrate. Therefore, co-administration of sacubitril/valsartan with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan. Appropriate care should be exercised when initiating or ending concomitant treatment with such medicinal products.</p><p>Metformin</p><p>Co-administration of sacubitril/valsartan with metformin reduced both Cmax and AUC of metformin by 23%. The clinical relevance of these findings is unknown. Therefore, when initiating therapy with sacubitril/valsartan in patients receiving metformin, the clinical status of the patient should be evaluated.</p><p><u>No significant interaction</u></p><p>No clinically meaningful drug-drug interaction was observed when sacubitril/valsartan was co- administered with digoxin, warfarin, hydrochlorothiazide, amlodipine, omeprazole, carvedilol or a combination of levonorgestrel/ethinyl estradiol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The use of sacubitril/valsartan is not recommended during the first trimester of pregnancy and is contraindicated during the second and third trimesters of pregnancy (see section 4.3).</p><p>Valsartan</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with ARBs, similar risks may exist for this class of medicinal product. Unless continued ARB therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ARBs should be stopped immediately and, if appropriate, alternative therapy should be started. Exposure to ARBs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).</p><p>Should exposure to ARBs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ARBs should be closely observed for hypotension (see section 4.3).</p><p>Sacubitril</p><p>There are no data from the use of sacubitril in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Sacubitril/valsartan</p><p>There are no data from the use of sacubitril/valsartan in pregnant women. Animal studies with sacubitril/valsartan have shown reproductive toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>It is not known whether sacubitril/valsartan is excreted in human milk. The components of Favval-SCT, sacubitril and valsartan, were excreted in the milk of lactating rats (see section 5.3). Because of the potential risk for adverse reactions in breast-fed newborns/infants, it is not recommended during breast-feeding. A decision should be made whether to abstain from breast- feeding or to discontinue Sacvalywhile breast-feeding, taking into account the importance of sacubitril/valsartan to the mother.</p><p><u>Fertility</u></p><p>There are no available data on the effect of sacubitril/valsartan on human fertility. No impairment of fertility was demonstrated in studies with it in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sacubitril/valsartan has a minor influence on the ability to drive and use machines. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions during treatment with sacubitril/valsartan were hypotension (17.6%), hyperkalaemia (11.6%) and renal impairment (10.1%) (see section 4.4). Angioedema was reported in patients treated with sacubitril/valsartan (0.5%) (see description of selected adverse reactions).</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to</p><p>&lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness <strong>Table 1 List of adverse reactions</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Hyperkalaemia*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness postural</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hypotension*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue disorders</strong></p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema*</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Renal impairment*</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure (renal failure, acute renal failure)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Hallucinations**</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paranoia</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr></tbody></table><p>*See description of selected adverse reactions.</p><p>&nbsp;</p><p>**Including auditory and visual hallucinations <u>Description of selected adverse reactions</u> Angioedema</p><p>Angioedema has been reported in patients treated with sacubitril/valsartan. In PARADIGM-HF, angioedema was reported in 0.5% of patients treated with sacubitril/valsartan, compared with 0.2% of patients treated with enalapril. A higher incidence of angioedema was observed in Black patients treated with sacubitril/valsartan (2.4%) and enalapril (0.5%) (see section 4.4).</p><p>Hyperkalaemia and serum potassium</p><p>In PARADIGM-HF, hyperkalaemia and serum potassium concentrations &gt;5.4 mmol/l were reported in 11.6% and 19.7% of sacubitril/valsartan-treated patients and 14.0% and 21.1% of enalapril-treated patients, respectively.</p><p>Blood pressure</p><p>In PARADIGM-HF, hypotension and clinically relevant low systolic blood pressure (&lt;90 mmHg and decrease from baseline of &gt;20 mmHg) were reported in 17.6% and 4.76% of sacubitril/valsartan-treated patients compared with 11.9% and 2.67% of enalapril-treated patients, respectively.</p><p>Renal impairment</p><p>In PARADIGM-HF, renal impairment was reported in 10.1% of sacubitril/valsartan-treated patients and 11.5% of enalapril-treated patients.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&bull;&nbsp; Saudi Arabia:</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textbox_x0020_9" o:spid="_x0000_s1026" type="#_x0000_t202"
 style='width:409.45pt;height:106.95pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
 <v:path arrowok="t"/>
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
    0in;margin-left:10.3pt;margin-bottom:.0001pt'>The<span style='letter-spacing:
    -.2pt'> </span>National<span style='letter-spacing:-.1pt'> </span>Pharmacovigilance<span
    style='letter-spacing:-.05pt'> </span>and<span style='letter-spacing:-.2pt'>
    </span>Drug<span style='letter-spacing:-.05pt'> </span>Safety<span
    style='letter-spacing:-.2pt'> </span>Centre<span style='letter-spacing:
    -.05pt'> </span><span style='letter-spacing:-.1pt'>(NPC)</span><o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:12.85pt;margin-right:0in;margin-bottom:
    0in;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.0pt;mso-list:
    l1 level1 lfo1;tab-stops:19.3pt'><![if !supportLists]><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
    dir=LTR></span>SFDA<span style='letter-spacing:-.1pt'> </span>Call<span
    style='letter-spacing:-.1pt'> </span>Center:<span style='letter-spacing:
    -.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:12.6pt;margin-right:0in;margin-bottom:
    0in;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.3pt;mso-list:
    l1 level1 lfo1;tab-stops:19.3pt'><![if !supportLists]><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span><![endif]><span dir=LTR></span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
    letter-spacing:-.1pt;text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
    <p class=MsoBodyText style='margin-left:0in'><o:p>&nbsp;</o:p></p>
    <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.3pt;
    mso-list:l1 level1 lfo1;tab-stops:19.3pt'><![if !supportLists]><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span><![endif]><span dir=LTR></span><span style='letter-spacing:
    -.1pt'>Website:https://ade.sfda.gov.sa/</span><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="552" height="149" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC)
o	SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa

o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:409.45pt;height:106.95pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available with regard to overdose in humans. A single dose of 617 mg valsartan/583 mg sacubitril and multiple doses of 463 mg valsartan/437 mg sacubitril (14 days) were studied in healthy volunteers and were well tolerated.</p><p>Hypotension is the most likely symptom of overdose due to the blood pressure lowering effects of sacubitril/valsartan. Symptomatic treatment should be provided.</p><p>The medicinal product is unlikely to be removed by haemodialysis due to high protein binding (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II receptor blockers (ARBs), other combinations, ATC code: C09DX04</p><p><u>Mechanism of action</u></p><p>Sacubitril/valsartan exhibits the mechanism of action of an angiotensin receptor neprilysin inhibitor by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan. The complementary cardiovascular benefits of sacubitril/valsartan in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the effects of angiotensin II by valsartan. NPs exert their effects by activating membrane-bound guanylyl</p><p>&nbsp;</p><p>cyclase-coupled receptors, resulting in increased concentrations of the second messenger cyclic guanosine monophosphate (cGMP), which could result in vasodilation, natriuresis and diuresis, increased glomerular filtration rate and renal blood flow, inhibition of renin and aldosterone release, reduction of sympathetic activity, and anti-hypertrophic and anti-fibrotic effects.</p><p>Valsartan inhibits detrimental cardiovascular and renal effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release. This prevents sustained activation of the renin-angiotensin-aldosterone system that would result in vasoconstriction, renal sodium and fluid retention, activation of cellular growth and proliferation, and subsequent maladaptive cardiovascular remodelling.</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamic effects of sacubitril/valsartan were evaluated after single and multiple dose administrations in healthy subjects and in patients with heart failure, and are consistent with simultaneous neprilysin inhibition and RAAS blockade. In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of sacubitril/valsartan resulted in an initial increase in natriuresis, increased urine cGMP, and decreased plasma levels of mid- regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) compared to valsartan. In a 21-day study in HFrEF patients, sacubitril/valsartan significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1 compared to baseline. The AT1- receptor was also blocked as evidenced by increased plasma renin activity and plasma renin concentrations. In the PARADIGM-HF study, sacubitril/valsartan decreased plasma NT-proBNP and increased plasma BNP and urine cGMP compared with enalapril. BNP is not a suitable biomarker of heart failure in patients treated with sacubitril/valsartan because BNP is a neprilysin substrate (see section 4.4). NT-proBNP is not a neprilysin substrate and is therefore a more suitable biomarker.</p><p>In a thorough QTc clinical study in healthy male subjects, single doses of sacubitril/valsartan 194 mg sacubitril/206 mg valsartan and 583 mg sacubitril/617 mg valsartan had no effect on cardiac repolarisation.</p><p>&nbsp;</p><p>Neprilysin is one of multiple enzymes involved in the clearance of amyloid-&beta; (A&beta;) from the brain and cerebrospinal fluid (CSF). Administration of sacubitril/valsartan 194 mg sacubitril/206 mg valsartan once daily for two weeks to healthy subjects was associated with an increase in CSF A&beta;1-38 compared to placebo; there were no changes in concentrations of CSF A&beta;1-40 and 1-42. The clinical relevance of this finding is not known (see section 5.3).</p><p><u>Clinical efficacy and safety</u></p><p>The 26 mg/24 mg, 51 mg/49 mg and 103 mg/97 mg strengths are in some publications referred to as 50, 100 or 200 mg.</p><p>PARADIGM-HF</p><p>PARADIGM-HF, the pivotal phase 3 study, was a multinational, randomised, double-blind study of 8,442 patients comparing sacubitril/valsartan to enalapril, both given to adult patients with chronic heart failure, NYHA class II-IV and reduced ejection fraction (left ventricular ejection fraction [LVEF] &le;40%, amended later to &le;35%) in addition to other heart failure therapy. The primary endpoint was the composite of cardiovascular (CV) death or hospitalisation for heart failure (HF). Patients with SBP &lt;100 mmHg, severe renal impairment (eGFR &lt;30 ml/min/1.73 m2) and severe hepatic impairment were excluded at screening and therefore not prospectively studied.</p><p>Prior to study participation, patients were well treated with standard of care therapy which included ACE inhibitors/ARBs (&gt;99%), beta blockers (94%), mineralocorticoid antagonists (58%) and diuretics (82%). The median follow-up duration was 27 months and patients were treated for up to 4.3 years.</p><p>Patients were required to discontinue their existing ACE inhibitor or ARB therapy and enter a sequential single-blind run-in period during which they received treatment with enalapril 10 mg twice daily, followed by single-blind treatment with sacubitril/valsartan 100 mg twice daily, increasing to 200 mg twice daily (see section 4.8 for discontinuations during this period). They were then randomised to the double-blind period of the study, during which they received either sacubitril/valsartan 200 mg or enalapril 10 mg twice daily [sacubitril/valsartan (n=4,209); enalapril (n=4,233)].</p><p>&nbsp;</p><p>The mean age of the population studied was 64 years of age and 19% were 75 years of age or older. At randomisation, 70% of patients were NYHA class II, 24% were class III and 0.7% were class IV. The mean LVEF was 29% and there were 963 (11.4%) patients with a baseline LVEF</p><p>&gt;35% and &le;40%.</p><p>In the sacubitril/valsartan group, 76% of patients remained on the target dose of 200 mg twice daily at the end of the study (mean daily dose of 375 mg). In the enalapril group, 75% of patients remained on the target dose of 10 mg twice daily at the end of the study (mean daily dose of 18.9 mg).</p><p>Sacubitril/valsartan was superior to enalapril, reducing the risk of cardiovascular death or heart failure hospitalisations to 21.8% compared to 26.5% for enalapril treated patients. The absolute risk reductions were 4.7% for the composite of the CV death or HF hospitalisation, 3.1% for CV death alone, and 2.8% for first HF hospitalisation alone. The relative risk reduction was 20% versus enalapril (see Table 2). This effect was observed early and was sustained throughout the duration of the study (see Figure 1). Both components contributed to the risk reduction. Sudden death&nbsp;&nbsp; accounted&nbsp;&nbsp; for&nbsp;&nbsp;&nbsp; 45%&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp; cardiovascular&nbsp;&nbsp;&nbsp; deaths&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp; was&nbsp;&nbsp;&nbsp; reduced&nbsp;&nbsp; by&nbsp;&nbsp;&nbsp; 20%&nbsp;&nbsp;&nbsp; in sacubitril/valsartan-treated patients compared to enalapril-treated patients (HR 0.80, p=0.0082). Pump failure accounted for 26% of cardiovascular deaths and was reduced by 21% in sacubitril/valsartan-treated patients compared to enalapril-treated patients (HR 0.79, p=0.0338). This risk reduction was consistently observed across subgroups including: gender, age, race, geography, NYHA class (II/III), ejection fraction, renal function, history of diabetes or hypertension, prior heart failure therapy, and atrial fibrillation.</p><p>Sacubitril/valsartan improved survival with a significant reduction in all-cause mortality of 2.8% (sacubitril/valsartan, 17%, enalapril, 19.8%). The relative risk reduction was 16% compared with enalapril (see Table 2).</p><p>Table 2 Treatment effect for the primary composite endpoint, its components and all-cause mortality over a median follow-up of 27 months</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sacubitril/ valsartan</strong></p></td><td style="vertical-align:top"><p><strong>Enalapril N=4,212</strong><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Image_x0020_10" o:spid="_x0000_i1028" type="#_x0000_t75"
   style='width:3.75pt;height:6pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
   <o:lock v:ext="edit" aspectratio="f"/>
  </v:shape><![endif]--><img width="5" height="8" src="data:image/png;base64,R0lGODlhBQAIAHcAMSH+GlNvZnR3YXJlOiBNaWNyb3NvZnQgT2ZmaWNlACH5BAEAAAAALAAAAAAFAAgAgAAAAAAAAAILhB+QGpuLlGxHmgIAOw==" /></strong></p></td><td style="vertical-align:top"><p><strong>Hazard ratio (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Relative </strong><strong>risk</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p><p><strong>***</strong></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=4,187</strong><strong><!--[if gte vml 1]><v:shape id="Image_x0020_11" o:spid="_x0000_i1027"
   type="#_x0000_t75" style='width:3.75pt;height:6pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
   <o:lock v:ext="edit" aspectratio="f"/>
  </v:shape><![endif]--><img width="5" height="8" src="data:image/png;base64,R0lGODlhBQAIAHcAMSH+GlNvZnR3YXJlOiBNaWNyb3NvZnQgT2ZmaWNlACH5BAEAAAAALAAAAAAFAAgAgAAAAAAAAAILhB+QGpuLlGxHmgIAOw==" /></strong>&nbsp;<strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>reduction</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Primary composite endpoint of CV death and heart failure hospitalisations*</p></td><td style="vertical-align:top"><p>914 (21.83)</p></td><td style="vertical-align:top"><p>1,117 (26.52)</p></td><td style="vertical-align:top"><p>0.80 (0.73, 0.87)</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>0.0000002</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Individual components of the primary composite endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>CV death**</p></td><td style="vertical-align:top"><p>558 (13.33)</p></td><td style="vertical-align:top"><p>693 (16.45)</p></td><td style="vertical-align:top"><p>0.80 (0.71, 0.89)</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>0.00004</p></td></tr><tr><td style="vertical-align:top"><p>First&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure hospitalisation</p></td><td style="vertical-align:top"><p>537 (12.83)</p></td><td style="vertical-align:top"><p>658 (15.62)</p></td><td style="vertical-align:top"><p>0.79 (0.71, 0.89)</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>0.00004</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Secondary endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>All-cause mortality</p></td><td style="vertical-align:top"><p>711 (16.98)</p></td><td style="vertical-align:top"><p>835 (19.82)</p></td><td style="vertical-align:top"><p>0.84 (0.76, 0.93)</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>0.0005</p></td></tr></tbody></table><p>*The primary endpoint was defined as the time to first event of CV death or hospitalisation for HF.</p><p>**CV death includes all patients who died up to the cut-off date irrespective of previous hospitalisation.</p><p>***One-sided p-value <!--[if gte vml 1]><v:shape
 id="Image_x0020_12" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:3.75pt;
 height:6pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="5" height="8" src="data:image/png;base64,R0lGODlhBQAIAHcAMSH+GlNvZnR3YXJlOiBNaWNyb3NvZnQgT2ZmaWNlACH5BAEAAAAALAAAAAAFAAgAgAAAAAAAAAILhB+QGpuLlGxHmgIAOw==" />&nbsp;Full analysis set</p><p>Figure 1 Kaplan-Meier curves for the primary composite endpoint and the CV death component</p><p><!--[if gte vml 1]><v:shape id="Image_x0020_13"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:472.5pt;height:165.75pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="630" height="221" src="data:image/png;base64,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" /></p><p><strong>&nbsp;</strong></p><p>TITRATION</p><p>TITRATION was a 12-week safety and tolerability study in 538 patients with chronic heart failure (NYHA class II&ndash;IV) and systolic dysfunction (left ventricular ejection fraction &le;35%) na&iuml;ve to ACE inhibitor or ARB therapy or on varying doses of ACE inhibitors or ARBs prior to study entry. Patients received a starting dose of sacubitril/valsartan of 50 mg twice daily and were up-titrated to 100 mg twice daily, then to the target dose of 200 mg twice daily, with either a 3-week or a 6-week regimen.</p><p>More patients who were na&iuml;ve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to &lt;10 mg enalapril/day) were able to achieve and maintain sacubitril/valsartan 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%). Overall, 76% of patients achieved and maintained the target dose of sacubitril/valsartan 200 mg twice daily without any dose interruption or down-titration over 12 weeks.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with sacubitril/valsartan in one or more subsets of the paediatric population in the treatment of heart failure (see section 4.2 for information on paediatric use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The valsartan contained within sacubitril/valsartan is more bioavailable than the valsartan in other marketed tablet formulations; 26 mg, 51 mg, and 103 mg of valsartan in sacubitril/valsartan</p><p>is equivalent to 40 mg, 80 mg and 160 mg of valsartan in other marketed tablet formulations, respectively.</p><p><u>Absorption</u></p><p>Following oral administration, sacubitril/valsartan dissociates into valsartan and the prodrug sacubitril. Sacubitril is further metabolised to the active metabolite LBQ657. These reach peak plasma concentrations in 2 hours, 1 hour, and 2 hours, respectively. The oral absolute bioavailability of sacubitril and valsartan is estimated to be more than 60% and 23%, respectively.</p><p>Following twice daily dosing of sacubitril/valsartan, steady-state levels of sacubitril, LBQ657 and valsartan are reached in three days. At steady state, sacubitril and valsartan do not accumulate significantly, while LBQ657 accumulates 1.6-fold. Administration with food has no clinically significant impact on the systemic exposures of sacubitril, LBQ657 and valsartan. Sacubitril/valsartan can be administered with or without food.</p><p><u>Distribution</u></p><p>Sacubitril, LBQ657 and valsartan are highly bound to plasma proteins (94-97%). Based on the comparison of plasma and CSF exposures, LBQ657 crosses the blood brain barrier to a limited extent (0.28%). The average apparent volume of distribution of valsartan and sacubitril were 75 litres to 103 litres, respectively.</p><p><u>Biotransformation</u></p><p>Sacubitril is readily converted to LBQ657 by carboxylesterases 1b and 1c; LBQ657 is not further metabolised to a significant extent. Valsartan is minimally metabolised, as only about 20% of the dose is recovered as metabolites. A hydroxyl metabolite of valsartan has been identified in plasma at low concentrations (&lt;10%).</p><p>Since CYP450-enzyme-mediated metabolism of sacubitril and valsartan is minimal, co- administration with medicinal products that impact CYP450 enzymes is not expected to impact the pharmacokinetics.</p><p>In vitro metabolism studies indicate that potential for CYP450 based drug interactions is low since there is limited metabolism of sacubitril/valsartan via CYP450 enzymes. Sacubitril/valsartan does not induce or inhibit CYP450 enzymes.</p><p><u>Elimination</u></p><p>Following oral administration, 52-68% of sacubitril (primarily as LBQ657) and ~13% of valsartan and its metabolites are excreted in urine; 37-48% of sacubitril (primarily as LBQ657) and 86% of valsartan and its metabolites are excreted in faeces.</p><p>Sacubitril, LBQ657 and valsartan are eliminated from plasma with a mean elimination half-life (T&frac12;) of approximately 1.43 hours, 11.48 hours, and 9.90 hours, respectively.</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of sacubitril, LBQ657 and valsartan were approximately linear over a sacubitril/valsartan dose range of 26 mg valsartan/24 mg sacubitril to 103 mg valsartan/97 mg sacubitril.</p><p><u>Special populations</u> Elderly patients</p><p>LBQ657 and valsartan exposure are increased in subjects over 65 years of age by 42% and 30%, respectively, compared to younger subjects.</p><p>Impaired renal function</p><p>A correlation was observed between renal function and systemic exposure to LBQ657 in patients with mild to severe renal impairment. The exposure of LBQ657 in patients with moderate (30 ml/min/1.73 m2 &le; eGFR &lt;60 ml/min/1.73 m2) and severe renal impairment (15 ml/min/1.73 m2</p><p>&le; eGFR &lt;30 ml/min/1.73 m2) was 1.4-fold and 2.2-fold higher compared to patients with mild renal impairment (60 ml/min/1.73 m2 &le; eGFR &lt;90 ml/min/1.73 m2), the largest group of patients enrolled in PARADIGM-HF). The exposure of valsartan was similar in patients with moderate and severe renal impairment compared to patients with mild renal impairment. No studies have been performed in patients undergoing dialysis. However, LBQ657 and valsartan are highly bound to plasma protein and therefore unlikely to be effectively removed by dialysis. Impaired hepatic function</p><p>In patients with mild to moderate hepatic impairment, the exposures of sacubitril increased by 1.5- and 3.4- fold, LBQ657 increased by 1.5- and 1.9-fold, and valsartan increased by 1.2-fold and 2.1-fold, respectively, compared to matching healthy subjects. However, in patients with mild to moderate hepatic impairment, the exposures of free concentrations of LBQ657 increased</p><p>by 1.47- and 3.08-fold, respectively, and the exposures of free concentrations of valsartan increased by 1.09-fold and 2.20-fold, respectively, compared to matching healthy subjects. Sacubitril/valsartan has not been studied in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (see sections 4.3 and 4.4).</p><p>Effect of gender</p><p>The pharmacokinetics of sacubitril/valsartan (sacubitril, LBQ657 and valsartan) are similar between male and female subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data (including studies with sacubitril and valsartan components and/or sacubitril/valsartan) reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and fertility.</p><p><u>Fertility, reproduction and development</u></p><p>Sacubitril/valsartan treatment during organogenesis resulted in increased embryofoetal lethality in rats at doses &ge;49 mg sacubitril/51 mg valsartan/kg/day (&le;0.72-fold the maximum recommended human dose [MRHD] on the basis of AUC) and rabbits at doses &ge;4.9 mg sacubitril/5.1 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively). It is teratogenic based on a low incidence of foetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at a sacubitril/valsartan dose of &ge;4.9 mg sacubitril/5.1 mg valsartan/kg/day. Cardiovascular abnormalities (mainly cardiomegaly) were observed in rabbit foetuses at a maternally non-toxic dose (1.46 mg sacubitril/1.54 mg valsartan/kg/day). A slight increase in two foetal skeletal variations (misshapen sternebra, sternebra bipartite ossification) was observed in rabbits at a sacubitril/valsartan dose of 4.9 mg sacubitril/5.1 mg valsartan/kg/day. The adverse embryofoetal effects of sacubitril/valsartan are attributed to the angiotensin receptor antagonist activity (see section 4.6).</p><p>Sacubitril treatment during organogenesis resulted in embryo-foetal lethality and embryo-foetal toxicity (decreased foetal body weights and skeletal malformations) in rabbits at doses associated with maternal toxicity (500 mg/kg/day; 5.7-fold the MRHD on the basis of LBQ657 AUC). A slight generalised delay in ossification was observed at doses of &gt;50 mg/kg/day. This finding is</p><p>not considered adverse. No evidence of embryo-foetal toxicity or teratogenicity was observed in rats treated with sacubitril. The embryo-foetal no-observed adverse effect level (NOAEL) for sacubitril was at least 750 mg/kg/day in rats and 200 mg/kg/day in rabbits (2.2-fold the MRHD on the basis of LBQ657 AUC).</p><p>Pre- and postnatal development studies in rats conducted with sacubitril at high doses up to 750 mg/kg/day (2.2-fold the MRHD on the basis of AUC) and valsartan at doses up to 600 mg/kg/day (0.86-fold the MRHD on the basis of AUC) indicate that treatment with sacubitril/valsartan during organogenesis, gestation and lactation may affect pup development and survival.</p><p><u>Other preclinical findings</u> Sacubitril/valsartan</p><p>The effects of sacubitril/valsartan on amyloid-&beta; concentrations in CSF and brain tissue were assessed in young (2-4 years old) cynomolgus monkeys treated with sacubitril/valsartan (24 mg sacubitril/26 mg valsartan/kg/day) for two weeks. In this study CSF A&beta; clearance in cynomolgus monkeys was reduced, increasing CSF A&beta;1-40, 1-42 and 1-38 levels; there was no corresponding increase in A&beta; levels in the brain. Increases in CSF A&beta;1-40 and 1-42 were not observed in a two-week healthy volunteer study in humans (see section 5.1). Additionally, in a toxicology study in cynomolgus monkeys treated with sacubitril/valsartan at 146 mg sacubitril/154 mg valsartan/kg/day for 39 weeks, there was no evidence for the presence of amyloid plaques in the brain. Amyloid content was not, however, measured quantitatively in this study.</p><p>Sacubitril</p><p>In juvenile rats treated with sacubitril (postnatal days 7 to 70), there was a reduction in age- related bone mass development and bone elongation. A study in adult rats showed only a minimal transient inhibitory effect on bone mineral density but not on any other parameters relevant for bone growth, suggesting no relevant effect of sacubitril on bone in adult patient populations under normal conditions. However, a mild transient interference of sacubitril with the early phase of fracture healing in adults cannot be excluded.</p><p>Valsartan</p><p>In juvenile rats treated with valsartan (postnatal days 7 to 70), doses as low as 1 mg/kg/day produced persistent irreversible kidney changes consisting of tubular nephropathy (sometimes accompanied by tubular epithelial necrosis) and pelvic dilatation. These kidney changes represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp; </strong><strong>Sacvaly 26/24:</strong></p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides and Titanium Dioxide.</p><p>Sacvaly 51/49:</p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides, Titanium Dioxide, FD&amp;C blue #2/Indigo Carmine AL 3% and 5% and FD&amp;C blue #2/Indigo Carmine Aluminum lake.</p><p>Sacvaly 103/97:</p><p><strong>The other ingredients are: </strong>Microcrystalline Cellulose, Low substituted Hydroxypropyl, Povidone, Isopropyl alcohol, Crospovidone, Silicon dioxide, Magnesium Stearate and Methylene chloride.</p><p><strong>Film Coating composition: </strong>HPMC 2910/Hypromellose, Di-Acetylated monoglycerides, Iron oxide Red and Titanium Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30⁰C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Pack contain 60 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Aljameah Street, Malaz quarter, Riyadh 12629, Saudi Arabia
Tel: +966 11 226 8850
Manufacture: Hetero Lab Unit III, Hyderabad, India
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>